Found 377 Barrett's Esophagus trials
A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines MK-4830 in combination with pembrolizumab in participants with PD-L1 positive NSCLC.
Study is enrolling patients with IgAN (IgA Nephropathy) to find out if oral atrasentan will delay worsening of kidney functions in comparison to placebo. Subjects will be asked to complete questionnaires, do a physical exam, perform ECG, give blood and urine samples, and weigh themselves.
Phase 2: To evaluate BICR-assessed objective response rate at each dose level of R-DXd. Phase 3:To evaluate BICR-assessed objective response rate with R-DXd treatment compared with investigator's choice of paclitaxel, PLD, gemcitabine, or topotecan. Objectives, outcome measures, and endpoints are located in Tables 3.1 and 3.2 of the protocol. Phase …
DPP4 is an enzyme that breaks down proteins that may affect blood sugar and the heart. We will recruit individuals from the Penn Biobank (cases, controls). Participants will be asked to complete a meal test, DXA, and echocardiogram with exercise. A cardiac MRI and related pilot study are optional.
The purpose of this study is to evaluate the safety, recommended dose, antitumor activity, and pharmacokinetics of JCAR017 in subjects with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The safety of JCAR017 in subjects who are receiving concurrent ibrutinib will also be evaluated.
Create a foundational resource for conducting and sharing ATN imaging and blood biomarker results in the context of the large clinically heterogenous brain-donor-enrolled multi-ADRC cohort. These imaging-plasma sets will be intrinsically linked to cognitive and neurobehavioral data collection, genetics and eventually neuropathology.
This post-market registry serves as an ongoing source of product performance, patient safety, and clinical outcomes for a variety of different products. The research design allows products to be added once they are released on the market. Patients are enrolled and followed according to their care provider’s normal care routine.
This research is being done to determine the maximum dose of an investigational drug called autologous desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) that can be safely given to patients with pemphigus vulgaris to target and kill only the B cells that are making the autoantibodies that attack DSG3.
This is an OLE for all subjects we currently have enrolled in BI 1305-0014 and 1305-0023. Subjects will be on either 9 mg or 18 mg of IP based on results from the current studies. Procedures involve safety labs, lung function testing, clinical labs, ECGs, PEs, AE collection.
Penn Medicine patients already participating in protocol INS1007 301 will be invited to participate in this study. The Pharmacokinetic (PK) portion of this substudy is designed to evaluate the amount of brensocatib present in your blood at certain time periods before and after the study drug is administered, and the …
